Imricor Medical Systems (ASX:IMR) said the Lausanne University Hospital in Switzerland performed its first procedure using the company's iCMR cardiac ablation device, according to a Wednesday filing with the Australian bourse.
The move makes the hospital the third site for the company's Visabl-AFL clinical trial being conducted to support the US Food and Drug Administration approval of the company's products, the filing said. It follows the activation of the Johns Hopkins Hospital in the US and the Cardiovascular Institute of South Paris in France.
The company's shares rose past 11% in recent Wednesday trade and earlier hit their highest since November 2021.
Price (AUD): $0.98, Change: $+0.10, Percent Change: +11.36%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。